Know more

About cookies

What is a "cookie"?

A "cookie" is a piece of information, usually small and identified by a name, which may be sent to your browser by a website you are visiting. Your web browser will store it for a period of time, and send it back to the web server each time you log on again.

Different types of cookies are placed on the sites:

  • Cookies strictly necessary for the proper functioning of the site
  • Cookies deposited by third party sites to improve the interactivity of the site, to collect statistics

Learn more about cookies and how they work

The different types of cookies used on this site

Cookies strictly necessary for the site to function

These cookies allow the main services of the site to function optimally. You can technically block them using your browser settings but your experience on the site may be degraded.

Furthermore, you have the possibility of opposing the use of audience measurement tracers strictly necessary for the functioning and current administration of the website in the cookie management window accessible via the link located in the footer of the site.

Technical cookies

Name of the cookie

Purpose

Shelf life

CAS and PHP session cookies

Login credentials, session security

Session

Tarteaucitron

Saving your cookie consent choices

12 months

Audience measurement cookies (AT Internet)

Name of the cookie

Purpose

Shelf life

atid

Trace the visitor's route in order to establish visit statistics.

13 months

atuserid

Store the anonymous ID of the visitor who starts the first time he visits the site

13 months

atidvisitor

Identify the numbers (unique identifiers of a site) seen by the visitor and store the visitor's identifiers.

13 months

About the AT Internet audience measurement tool :

AT Internet's audience measurement tool Analytics is deployed on this site in order to obtain information on visitors' navigation and to improve its use.

The French data protection authority (CNIL) has granted an exemption to AT Internet's Web Analytics cookie. This tool is thus exempt from the collection of the Internet user's consent with regard to the deposit of analytics cookies. However, you can refuse the deposit of these cookies via the cookie management panel.

Good to know:

  • The data collected are not cross-checked with other processing operations
  • The deposited cookie is only used to produce anonymous statistics
  • The cookie does not allow the user's navigation on other sites to be tracked.

Third party cookies to improve the interactivity of the site

This site relies on certain services provided by third parties which allow :

  • to offer interactive content;
  • improve usability and facilitate the sharing of content on social networks;
  • view videos and animated presentations directly on our website;
  • protect form entries from robots;
  • monitor the performance of the site.

These third parties will collect and use your browsing data for their own purposes.

How to accept or reject cookies

When you start browsing an eZpublish site, the appearance of the "cookies" banner allows you to accept or refuse all the cookies we use. This banner will be displayed as long as you have not made a choice, even if you are browsing on another page of the site.

You can change your choices at any time by clicking on the "Cookie Management" link.

You can manage these cookies in your browser. Here are the procedures to follow: Firefox; Chrome; Explorer; Safari; Opera

For more information about the cookies we use, you can contact INRAE's Data Protection Officer by email at cil-dpo@inrae.fr or by post at :

INRAE

24, chemin de Borde Rouge -Auzeville - CS52627 31326 Castanet Tolosan cedex - France

Last update: May 2021

Menu Logo Principal logo Université Clermont Auvergne & associés

Human Nutrition Unit

Zone de texte éditable et éditée et rééditée

Anne TOURNADRE, MD, PhD

Activities

Email : contact
Tel : +33 (0)4

Sarcopenia is a disease recognized by WHO on the international classification of ICD diseases (M62.8). Its prevalence increases with age and associated chronic diseases. Thus it affects about 10% of the over 65s, 50% of the over 80s. Its prevalence is also increased in chronic diseases, affecting 30% of patients with chronic rheumatic diseases. During chronic inflammatory rheumatic diseases (rheumatoid arthritis, spondyloarthritis, inflammatory myopathies), changes in body composition related to loss of mobility, inflammation, insulin resistance occur early. Muscle loss associated with increased adipose tissue is observed and defines the sarcopenic adiposity phenotype which contributes to cardiovascular and metabolic comorbidities and increased morbidity and mortality. In chronic inflammatory rheumatic diseases, the management of cardio-metabolic comorbidities (sarcopenic adiposity, metabolic syndrome, cardiovascular risk, osteoporosis) is therefore one of the major challenges. For this reason, the research activity aims to explore sarcopenia, metabolic disorders and associated comorbidities in chronic inflammatory joint and muscle diseases with reduced mobility such rheumatic diseases. Such knowledge is essential for the development of targeted, personalized and multimodal innovative therapeutic and preventive strategies based on biotherapies, nutrition and physical activity.

Research Activities

Characterization of the sarcopenia-associated phenotypes in chronic inflammatory rheumatic diseases (rheumatoid arthritis, spondyloarthritis, inflammatory myopathies): changes in muscle mass, body fat, and bone mass, metabolic disorders and associated cardiovascular comorbidities, energy expenditure taking into account the effect of treatments during a longitudinal follow-up.

Identification of mechanisms of sarcopenia and potential therapeutic targets during chronic inflammation: muscle lipotoxicity, impact of cytokine inhibitors and diet, identification of a biological signature in relation to muscle lipotoxicity and sarcopenia.

Development of diagnostic and monitoring tools: validation of sarcopenia biomarker on patients cohort, design predictive algorithms for a personalized prevention and care strategy.

Develop new therapeutic strategies combining targeted biotherapies, nutrition, physical activity.

Publications

  • Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, Frayssac T, Mathieu S, Malochet-Guinamand S, Soubrier M. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J  Cachexia Sarcopenia Muscle. 2017 Aug;8(4):639-646.
  • Tournadre A, Pereira B, Dubost JJ, Rincheval N, Rat AC, Combe B, Soubrier M. Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up. Clin Exp Rheumatol. 2017 Mar-Apr;35(2):296-302.
  • Nourisson C, Soubrier M, Mulliez A, Baillet A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Schaeverbeke T, Sibilia J, Vittecoq O, Ravaud P, Gottenberg JE, Mariette X, Tournadre A. Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry. RMD Open. 2017 Nov 1;3(2):e000515.
  • Marouen S, du Cailar G, Audo R, Lukas C, Vial G, Tournadre A, Barrat E, Ribstein J, Combe B, Morel J, Daien CI. Sodium excretion is higher in patients with rheumatoid arthritis than in matched controls. PLoS One. 2017 Oct 13;12(10):e0186157.
  • Malochet-Guinamand S, Pereira B, Tatar Z, Tournadre A, Moltó A, Dougados M, Soubrier M. Prevalence and risk factors of low bone mineral density in spondyloarthritis and prevalence of vertebral fractures. BMC Musculoskelet Disord. 2017 Aug 22;18(1):357.

Curriculum Vitae

Current position : Professeur des universités-Praticien hospitalier, Department of rheumatology Hôpital G. Montpied, CHU de Clermont-Ferrand 63003 Clermont-Ferrand Cedex1
Medical Degree Course: Medical Doctor, University of  Clermont-Ferrand (2003) 
Scientific Degree Course:
- Habilitation à Diriger des Recherches / Accreditation to Supervise Research, University of Auvergne, Clermont-Ferrand  (2015)
- PhD, University of  Claude Bernard LYON I (2010)
- Research fellowship 2001/2002 : Clinical and Molecular Rheumatology Division Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (Pr A. Rosen et Dr K. Nagaraju)
        
Research Team :
Alimentation Santé MusculoSquelettique, Unité de Nutrition Humaine,  UMR 1019 INRA/Université d’Auvergne
Awards or grants:
- Programme Hospitalier de Recherche Clinique 2004 «Soluble IL-2 receptor: a biomarker for assessing myositis activity.»
- Programme Hospitalier de Recherche Clinique Interregional 2007 «Toll-Like Receptors (TLR) expression, Th1 and Th17 response, in inflammatory myopathiesdans les myopathies inflammatoires »
- Programme Hospitalier de Recherche Clinique Interregional 2013 « Eccentric Exercise and Cachexia in Rheumatoid Arthritis (EECRA) »
- Bourse Sirius UCB 2015-2016 « Lipidomic analysis of HDL in inflammatory rheumatic diseases: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis »
- Bourse Passerelle Pfizer 2017 «Evolution of total energy expenditure and its various components in active rheumatoid arthritis treated with anti-TNF agents and comparison with healthy subjects (EDEn-PRAc)»